title: [Impact of taxanes in the adjuvant setting of node-negative breast cancers].
abstract: The use of regimens with adjuvant taxanes reduces the risk of recurrence and improves survival in patients with node-positive breast cancer, but the use of taxanes in node-negative breast cancer is still to be defined. The aim of this study is to evaluate the role of taxanes in high-risk node-negative breast cancer. Two categories of studies were reviewed: studies that evaluated both node-positive and node-negative breast cancers, and studies that included only high-risk node-negative breast cancers. Three phase-III studies that evaluated both negative and positive nodes did not show any benefit of the use of taxanes according to the node-negative subgroup analyses, versus two studies (European Cooperative Trial in Operable Breast Cancer [ECTO] et Grupo Español de Investigación del Cáncer de Mama [GEICAM]) that showed a significant difference in disease-free survival. In view of these studies, the role of taxanes in node-negative breast cancer is still controversial and the results of the ongoing trials may respond to this subject.
authors.affiliation: Hôpital Abderrahmane Mami, service d'oncologie médicale, rue de l'Hôpital, 2080 Ariana, Tunisie. aymen.lagha@hotmail.com
authors.forename: Aymen
authors.initials: A
authors.lastname: Lagha
authors.forename: Nesrine
authors.initials: N
authors.lastname: Chraiet
authors.forename: Soumaya
authors.initials: S
authors.lastname: Labidi
authors.forename: Sarra
authors.initials: S
authors.lastname: Krimi
authors.forename: Mouna
authors.initials: M
authors.lastname: Ayadi
authors.forename: Joseph
authors.initials: J
authors.lastname: Gligorov
authors.forename: Hamouda
authors.initials: H
authors.lastname: Boussen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D013629:Tamoxifen / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D043823:Taxoids; D013629:Tamoxifen; D000077143:Docetaxel; D015251:Epirubicin; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D005472:Fluorouracil; D008727:Methotrexate
keywords: adjuvant chemotherapy; breast cancer; docetaxel; node-negative; paclitaxel; taxanes